Praluzatamab
Based on 1 Customer Validation
Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers.
For research use only. We do not sell to patients.
- Purity: 99.14%
- CAS No.: 2145109-70-0
- Molecular Weight:146.9 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
ALCAM/CD166
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:H292 tumor-bearing mice (female, 8 weeks, 18-25 g, injected subcutaneously in both flanks with 5 × 106 H292 human lung cancer cells)[2]
-
Dosage:10, 110, 510 µg or 5 mg/kg
-
Administration:Intravenous injection (i.v.)
-
Result:At 72 hours after injection, the tumor uptake was the highest in the 10 µg and 110 µg groups.
Reduced the size of the tumor.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized ALCAM/CD166 Protein, Human (HEK293, Fc, HY-P7471) can bind Praluzatamab. The EC50 for this effect is 13.78 ng/mL. -
Flow cytometric analysis of 106 Jurkat cells with Praluzatamab (HY-P99788, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control
Chemical Information
-
CAS No. 2145109-70-0
-
Appearance Liquid
-
Molecular Weight 146.9 kDa
-
Color Colorless to light yellow
-
SMILES
[Praluzatamab]
-
Synonyms
CX-191; CX-2009 Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Martín-Sabroso C, et al. Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. Pharmaceutics. 2021 Oct 15;13(10):1705. [Content Brief]
[2]. Chomet M, et al. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice. Theranostics. 2020 Apr 27;10(13):5815-5828. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz